According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other analysts also recently issued research reports about the company. Jefferies Financial Group upgraded Catalent from a hold rating to a buy rating and boosted their price target for the company from $50.00 to $62.00 in a research note on Friday, June 21st. ValuEngine upgraded Catalent from a hold rating to a buy rating in a research note on Monday, April 15th. UBS Group boosted their price target on Catalent to $64.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. Finally, Morgan Stanley boosted their price target on Catalent from $46.00 to $50.00 and gave the company an overweight rating in a research note on Tuesday, April 16th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Catalent has a consensus rating of Buy and an average price target of $55.14.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.07. The business had revenue of $617.50 million for the quarter, compared to the consensus estimate of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.41 EPS. Sell-side analysts expect that Catalent will post 1.71 earnings per share for the current year.
In other news, insider Barry Littlejohns sold 15,940 shares of the company’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $53.53, for a total value of $853,268.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gregory T. Lucier bought 2,000 shares of the stock in a transaction dated Thursday, May 9th. The stock was bought at an average price of $45.08 per share, for a total transaction of $90,160.00. The disclosure for this purchase can be found here. Insiders bought 56,500 shares of company stock worth $2,542,845 in the last 90 days. Company insiders own 1.40% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Nordea Investment Management AB boosted its position in Catalent by 1.3% during the first quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock worth $4,438,000 after purchasing an additional 1,350 shares in the last quarter. Zions Bancorporation N.A. purchased a new position in Catalent during the first quarter worth approximately $61,000. Westfield Capital Management Co. LP boosted its position in Catalent by 29.3% during the first quarter. Westfield Capital Management Co. LP now owns 448,946 shares of the company’s stock worth $18,223,000 after purchasing an additional 101,645 shares in the last quarter. Lazard Asset Management LLC boosted its position in Catalent by 149.5% during the first quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock worth $30,085,000 after purchasing an additional 444,120 shares in the last quarter. Finally, Swiss National Bank boosted its position in Catalent by 3.4% during the first quarter. Swiss National Bank now owns 264,970 shares of the company’s stock worth $10,755,000 after purchasing an additional 8,800 shares in the last quarter. Institutional investors own 96.85% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Cost of Goods Sold (COGS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.